{"pmid":32311448,"title":"COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up.","text":["COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up.","Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.","J Am Coll Cardiol","Bikdeli, Behnood","Madhavan, Mahesh V","Jimenez, David","Chuich, Taylor","Dreyfus, Isaac","Driggin, Elissa","Nigoghossian, Caroline Der","Ageno, Walter","Madjid, Mohammad","Guo, Yutao","Tang, Liang V","Hu, Yu","Giri, Jay","Cushman, Mary","Quere, Isabelle","Dimakakos, Evangelos P","Gibson, C Michael","Lippi, Giuseppe","Favaloro, Emmanuel J","Fareed, Jawed","Caprini, Joseph A","Tafur, Alfonso J","Burton, John R","Francese, Dominic P","Wang, Elizabeth Y","Falanga, Anna","McLintock, Claire","Hunt, Beverley J","Spyropoulos, Alex C","Barnes, Geoffrey D","Eikelboom, John W","Weinberg, Ido","Schulman, Sam","Carrier, Marc","Piazza, Gregory","Beckman, Joshua A","Steg, P Gabriel","Stone, Gregg W","Rosenkranz, Stephan","Goldhaber, Samuel Z","Parikh, Sahil A","Monreal, Manuel","Krumholz, Harlan M","Konstantinides, Stavros V","Weitz, Jeffrey I","Lip, Gregory Y H","32311448"],"abstract":["Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic."],"journal":"J Am Coll Cardiol","authors":["Bikdeli, Behnood","Madhavan, Mahesh V","Jimenez, David","Chuich, Taylor","Dreyfus, Isaac","Driggin, Elissa","Nigoghossian, Caroline Der","Ageno, Walter","Madjid, Mohammad","Guo, Yutao","Tang, Liang V","Hu, Yu","Giri, Jay","Cushman, Mary","Quere, Isabelle","Dimakakos, Evangelos P","Gibson, C Michael","Lippi, Giuseppe","Favaloro, Emmanuel J","Fareed, Jawed","Caprini, Joseph A","Tafur, Alfonso J","Burton, John R","Francese, Dominic P","Wang, Elizabeth Y","Falanga, Anna","McLintock, Claire","Hunt, Beverley J","Spyropoulos, Alex C","Barnes, Geoffrey D","Eikelboom, John W","Weinberg, Ido","Schulman, Sam","Carrier, Marc","Piazza, Gregory","Beckman, Joshua A","Steg, P Gabriel","Stone, Gregg W","Rosenkranz, Stephan","Goldhaber, Samuel Z","Parikh, Sahil A","Monreal, Manuel","Krumholz, Harlan M","Konstantinides, Stavros V","Weitz, Jeffrey I","Lip, Gregory Y H"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311448","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jacc.2020.04.031","keywords":["coronavirus disease 2019","sars-cov-2","anticoagulant","antiplatelet","antithrombotic therapy","thrombosis"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Thrombotic"],"_version_":1664632501340995584,"score":8.518259,"similar":[{"pmid":32291094,"pmcid":"PMC7146714","title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19.","text":["Incidence of thrombotic complications in critically ill ICU patients with COVID-19.","INTRODUCTION: COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. Reports on the incidence of thrombotic complications are however not available. METHODS: We evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 Dutch university hospitals and 1 Dutch teaching hospital. RESULTS: We studied 184 ICU patients with proven COVID-19 pneumonia of whom 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. All patients received at least standard doses thromboprophylaxis. The cumulative incidence of the composite outcome was 31% (95%CI 20-41), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (n = 25, 81%). Age (adjusted hazard ratio (aHR) 1.05/per year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time > 3 s or activated partial thromboplastin time > 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of thrombotic complications. CONCLUSION: The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high. Our findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence.","Thromb Res","Klok, F A","Kruip, M J H A","van der Meer, N J M","Arbous, M S","Gommers, D A M P J","Kant, K M","Kaptein, F H J","van Paassen, J","Stals, M A M","Huisman, M V","Endeman, H","32291094"],"abstract":["INTRODUCTION: COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. Reports on the incidence of thrombotic complications are however not available. METHODS: We evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 Dutch university hospitals and 1 Dutch teaching hospital. RESULTS: We studied 184 ICU patients with proven COVID-19 pneumonia of whom 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. All patients received at least standard doses thromboprophylaxis. The cumulative incidence of the composite outcome was 31% (95%CI 20-41), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (n = 25, 81%). Age (adjusted hazard ratio (aHR) 1.05/per year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time > 3 s or activated partial thromboplastin time > 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of thrombotic complications. CONCLUSION: The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high. Our findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence."],"journal":"Thromb Res","authors":["Klok, F A","Kruip, M J H A","van der Meer, N J M","Arbous, M S","Gommers, D A M P J","Kant, K M","Kaptein, F H J","van Paassen, J","Stals, M A M","Huisman, M V","Endeman, H"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291094","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.thromres.2020.04.013","keywords":["covid-19","deep vein thrombosis","pulmonary embolism","stroke","thromboprophylaxis"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Dutch","Dutch","CTPA"],"countries":["Netherlands"],"countries_codes":["NLD|Netherlands"],"_version_":1664636192751091712,"score":577.64276},{"pmid":32327870,"pmcid":"PMC7176384","title":"[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].","text":["[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].","The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.","Rev Esp Cardiol","Vivas, David","Roldan, Vanessa","Esteve-Pastor, Maria Asuncion","Roldan, Inmaculada","Tello-Montoliu, Antonio","Ruiz-Nodar, Juan Miguel","Cosin-Sales, Juan","Maria Gamez, Jose","Consuegra, Luciano","Luis Ferreiro, Jose","Marin, Francisco","Arrarte, Vicente","Anguita, Manuel","Cequier, Angel","Perez-Villacastin, Julian","32327870"],"abstract":["The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy."],"journal":"Rev Esp Cardiol","authors":["Vivas, David","Roldan, Vanessa","Esteve-Pastor, Maria Asuncion","Roldan, Inmaculada","Tello-Montoliu, Antonio","Ruiz-Nodar, Juan Miguel","Cosin-Sales, Juan","Maria Gamez, Jose","Consuegra, Luciano","Luis Ferreiro, Jose","Marin, Francisco","Arrarte, Vicente","Anguita, Manuel","Cequier, Angel","Perez-Villacastin, Julian"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327870","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.recesp.2020.04.006","keywords":["antithrombotics","covid-19","covid-19, coronavirus infectious disease-19","coronavirus","doac, direct action oral anticoagulant","lmwh, low-molecular-weight heparin","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus-2","thrombosis","vka, vitamin k antagonist","vted, venous thromboembolic disease"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1664996914817400832,"score":564.4658},{"pmid":32304577,"title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","text":["Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.","Br J Haematol","Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos","32304577"],"abstract":["Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present."],"journal":"Br J Haematol","authors":["Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304577","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjh.16727","keywords":["sars-cov-2","anticoagulant","prophylaxis","thromboembolism","thrombosis"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["thromboprophylaxis"],"_version_":1664632934588481537,"score":484.37112},{"pmid":32294321,"title":"Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","text":["Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.","Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5].","J Thromb Haemost","Hermans, C","Lambert, C","32294321"],"abstract":["Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5]."],"journal":"J Thromb Haemost","authors":["Hermans, C","Lambert, C"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294321","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14845","keywords":["covid-19","emicizumab","pandemic","clotting factor concentrates","direct oral anticoagulants","hemophilia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636192764723200,"score":430.78568},{"pmid":32305883,"title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.","text":["Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.","Coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus strain disease, has recently emerged in China and rapidly spread worldwide. This novel strain is highly transmittable and severe disease has been reported in up to 16% of hospitalized cases. More than 600,000 cases have been confirmed and the number of deaths is constantly increasing. COVID-19 hospitalized patients, especially those suffering from severe respiratory or systemic manifestations, fall under the spectrum of the acutely ill medical population, which is at increased venous thromboembolism risk. Thrombotic complications seem to emerge as an important issue in patients infected with COVID-19. Preliminary reports on COVID-19 patients' clinical and laboratory findings include thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and disseminated intravascular coagulation. As the pandemic is spreading and the whole picture is yet unknown, we highlight the importance of coagulation disorders in COVID-19 infected patients and review relevant data of previous coronavirus epidemics caused by the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV).","J Clin Virol","Giannis, Dimitrios","Ziogas, Ioannis A","Gianni, Panagiota","32305883"],"abstract":["Coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus strain disease, has recently emerged in China and rapidly spread worldwide. This novel strain is highly transmittable and severe disease has been reported in up to 16% of hospitalized cases. More than 600,000 cases have been confirmed and the number of deaths is constantly increasing. COVID-19 hospitalized patients, especially those suffering from severe respiratory or systemic manifestations, fall under the spectrum of the acutely ill medical population, which is at increased venous thromboembolism risk. Thrombotic complications seem to emerge as an important issue in patients infected with COVID-19. Preliminary reports on COVID-19 patients' clinical and laboratory findings include thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and disseminated intravascular coagulation. As the pandemic is spreading and the whole picture is yet unknown, we highlight the importance of coagulation disorders in COVID-19 infected patients and review relevant data of previous coronavirus epidemics caused by the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV)."],"journal":"J Clin Virol","authors":["Giannis, Dimitrios","Ziogas, Ioannis A","Gianni, Panagiota"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305883","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jcv.2020.104362","keywords":["covid-19","mers-cov","sars-cov","coagulation","coronavirus","thrombosis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["China","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664641855671762944,"score":339.79794}]}